59618 Lebrikizumab improves itch, itch interference on sleep and skin pain in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab - 02/09/25

Doi : 10.1016/j.jaad.2025.05.247

Gil Yosipovitch
University of Miami Miller School of Medicine, Miami, FL, USA

Lindsay Ackerman
U.S. Dermatology Partners, Phoenix AZ

Jerry Bagel
Schwweiger Dermatology Group, East Windsor NJ, USA

Evangeline Pierce
Eli Lilly and Company

Amber Reck Atwater
Distinctive Dermatology, Great Valls, VA

Cynthia Harris
Eli Lilly and Company

Maria Silk
Eli Lilly and Company

Jennifer Proper
Eli Lilly and Company

Sonia Montmayeur
Eli Lilly and Company

Matthew Zirwas
Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA

Eric Simpson
Oregon Health & Science University, Portland, OR

Il testo completo di questo articolo è disponibile in PDF.

Commercial Disclosure: This study is sponsored by Eli Lilly and Company

Esportazione

Vol 93 - N° 3S

P. AB61 - settembre 2025 Ritorno al numero

Articolo precedente

62650 Late Onset Dermal Filler Reactions Preceded by GI Illness: An International Review
Harrison White, Alanis Villanueva, Dr. Kira Minkis

| Articolo seguente

63719 Levels of Motivation for the Prevention and Treatment of Skin Cancer in Cutaneous Oncology Patients Undergoing Mohs Micrographic Surgery
Frank Jing, Jorge Rios-Duarte, Allison Robbins, Elliott Campbell, Austin Todd, Nahid Vidal

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

connettersi o creare un account

59618 Lebrikizumab improves itch, itch interference on sleep and skin pain in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab - 02/09/25

Citazioni Export

File

Contenuto

Il mio account

Aide & support

Dichiarazione CNIL